Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9538.3333
Address
16 Miles Street Mulgrave, Victoria (VIC) 3170
Description
Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. It has developed and patented miniaturised confocal microscopes. Its products include FIVE2 and Customisation options. The company was founded by Martin Harris and Peter Maxwell Delaney in 1994 and is headquartered in Mulgrave, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.07 - 0.26
Trade Value (12mth)
AU$9,141.00
1 week
-15.38%
1 month
-17.5%
YTD
94.12%
1 year
120%
All time high
0.65
EPS 3 yr Growth
100.00%
EBITDA Margin
-679.10%
Operating Cashflow
-$6m
Free Cash Flow Return
-67.20%
ROIC
-70.90%
Interest Coverage
-331.00
Quick Ratio
7.40
Shares on Issue (Fully Dilluted)
835m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.01
Date | Announcements |
---|---|
30 August 24 |
Appendix 4E Preliminary Final Report
×
Appendix 4E Preliminary Final Report |
30 August 24 |
OIL 2024 Annual Report
×
OIL 2024 Annual Report |
30 August 24 |
Appendix 4G & Corporate Governance Statement
×
Appendix 4G & Corporate Governance Statement |
19 August 24 |
Optiscan Signs MOU with University of Minnesota
×
Optiscan Signs MOU with University of Minnesota |
31 July 24 |
OIL June 2024 Quarterly Report and Appendix 4C
×
OIL June 2024 Quarterly Report and Appendix 4C |
29 July 24 |
Optiscan Delivers Major Milestone in Telepathology Platform
×
Optiscan Delivers Major Milestone in Telepathology Platform |
15 July 24 |
Optiscan Receives Ethical Clearance for Breast Cancer Study
×
Optiscan Receives Ethical Clearance for Breast Cancer Study |
12 July 24 |
Notification regarding unquoted securities - OIL
×
Notification regarding unquoted securities - OIL |
01 July 24 |
Optiscan 2024 Roadshow Presentation
×
Optiscan 2024 Roadshow Presentation |
04 June 24 |
Optiscan Reveals InVue Imaging Device for Precision Surgery
×
Optiscan Reveals InVue Imaging Device for Precision Surgery |
16 May 24 |
Optiscan Webinar Investor Presentation
×
Optiscan Webinar Investor Presentation |
13 May 24 |
Optiscan Signs Know-How Agreement with Mayo Clinic
×
Optiscan Signs Know-How Agreement with Mayo Clinic |
13 May 24 |
Optiscan Webinar Following Mayo Clinic Agreement
×
Optiscan Webinar Following Mayo Clinic Agreement |
30 April 24 |
OIL March 2024 Quarterly Report and Appendix 4C
×
OIL March 2024 Quarterly Report and Appendix 4C |
17 April 24 |
Change in substantial holding
×
Change in substantial holding |
02 April 24 |
Optiscan appoints US Clinical & Regulatory Heads
×
Optiscan appoints US Clinical & Regulatory Heads |
20 March 24 |
Optiscan receives R&D Tax Incentive Rebate
×
Optiscan receives R&D Tax Incentive Rebate |
23 February 24 |
OIL Appendix 4D and 31 December 2023 Half-year report
×
OIL Appendix 4D and 31 December 2023 Half-year report |
13 February 24 |
Optiscan receives $3 million CRC-P Industry Grant
×
Optiscan receives $3 million CRC-P Industry Grant |
31 January 24 |
OIL December 2023 Quarterly Report and Appendix 4C
×
OIL December 2023 Quarterly Report and Appendix 4C |
13 December 23 |
Release of securities from escrow
×
Release of securities from escrow |
06 December 23 |
Application for quotation of securities - OIL
×
Application for quotation of securities - OIL |
06 December 23 |
Notification of cessation of securities - OIL
×
Notification of cessation of securities - OIL |
06 December 23 |
Section 708A Cleansing Notice
×
Section 708A Cleansing Notice |
23 November 23 |
OIL Managing Director's Presentation & Chair's Address
×
OIL Managing Director's Presentation & Chair's Address |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.